Exagen Statistics

Total Valuation

Exagen has a market cap or net worth of $73.02 million. The enterprise value is $74.73 million.

Market Cap	73.02M
Enterprise Value	74.73M

Important Dates

The last earnings date was Tuesday, November 12, 2024, before market open.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Exagen has 17.39 million shares outstanding. The number of shares has increased by 3.06% in one year.

Current Share Class	17.39M
Shares Outstanding	17.39M
Shares Change (YoY)	+3.06%
Shares Change (QoQ)	+0.42%
Owned by Insiders (%)	14.01%
Owned by Institutions (%)	28.10%
Float	6.62M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.36
Forward PS	1.20
PB Ratio	5.56
P/TBV Ratio	5.67
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1.34
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.05, with a Debt / Equity ratio of 1.84.

Current Ratio	4.05
Quick Ratio	3.58
Debt / Equity	1.84
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-6.88

Financial Efficiency

Return on equity (ROE) is -83.86% and return on invested capital (ROIC) is -21.54%.

Return on Equity (ROE)	-83.86%
Return on Assets (ROA)	-18.42%
Return on Capital (ROIC)	-21.54%
Revenue Per Employee	$311,458
Profits Per Employee	-$94,564
Employee Count	179
Asset Turnover	1.07
Inventory Turnover	8.88

Taxes

In the past 12 months, Exagen has paid $33,000 in taxes.

Income Tax	33,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +167.18% in the last 52 weeks. The beta is 1.35, so Exagen's price volatility has been higher than the market average.

Beta (5Y)	1.35
52-Week Price Change	+167.18%
50-Day Moving Average	2.85
200-Day Moving Average	2.22
Relative Strength Index (RSI)	80.15
Average Volume (20 Days)	65,647

Short Selling Information

The latest short interest is 52,214, so 0.30% of the outstanding shares have been sold short.

Short Interest	52,214
Short Previous Month	23,450
Short % of Shares Out	0.30%
Short % of Float	0.79%
Short Ratio (days to cover)	3.12

Income Statement

In the last 12 months, Exagen had revenue of $55.75 million and -$16.93 million in losses. Loss per share was -$0.94.

Revenue	55.75M
Gross Profit	32.78M
Operating Income	-15.40M
Pretax Income	-17.28M
Net Income	-16.93M
EBITDA	-13.58M
EBIT	-15.40M
Loss Per Share	-$0.94

Full Income Statement

Balance Sheet

The company has $22.04 million in cash and $23.74 million in debt, giving a net cash position of -$1.70 million or -$0.10 per share.

Cash & Cash Equivalents	22.04M
Total Debt	23.74M
Net Cash	-1.70M
Net Cash Per Share	-$0.10
Equity (Book Value)	12.87M
Book Value Per Share	0.75
Working Capital	26.78M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-5.29M
Capital Expenditures	-475,000
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 58.80%, with operating and profit margins of -27.62% and -30.36%.

Gross Margin	58.80%
Operating Margin	-27.62%
Pretax Margin	-30.30%
Profit Margin	-30.36%
EBITDA Margin	-24.37%
EBIT Margin	-27.62%
FCF Margin	-11.18%

Dividends & Yields

Exagen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.06%
Shareholder Yield	-3.06%
Earnings Yield	-23.18%
FCF Yield	n/a

Analyst Forecast

The average price target for Exagen is $7.00, which is 66.67% higher than the current price. The consensus rating is "Buy".

Price Target	$7.00
Price Target Difference	66.67%
Analyst Consensus	Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	14.15%
EPS Growth Forecast (5Y)	-13.30%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Exagen has an Altman Z-Score of -7.81 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.81
Piotroski F-Score	3